Prices delayed by at least 15 minutes | Print


Nuformix PLC (NFX)

ORD 0.1P
Sell: 0.18p|Buy: 0.2p|Change: 0 (0%)

Open 

0.18p


Previous close 

0.19p


Trade high 

0.1909p


Volume 

2,110,612


Year high 

0.44p


Year low 

0.18p


Dividend yield 

-


Market capitalisation 

£1.56 mn


P/E ratio 

-


ISIN 

GB00BYW79Y38


This share can be held in a Dealing accountISALifetime ISAJISASIPPand can be used with Dividend reinvestment

Share price

Performance 31/03/2024

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
Nuformix PLC 0.00
More...

Company profile

Nuformix PLC is a pharmaceutical development company. It operates in the field of pharmaceutical development targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.

Sector 

Healthcare


News

Recent trades

DateTimePriceQuantityValue (£)
28/03/202403:40:240.189,52417.14
28/03/202401:40:540.1909500,000954.50
28/03/202410:34:110.1856962,0111,785.49
28/03/202409:59:060.185529,563979.69
28/03/202408:55:070.18514,51426.85

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.